METHOD FOR MEASURING THE RESPONSE OF A TISSUE TO AN ELECTROMAGNETIC FIELD
The present invention relates to a method for measuring the response of the tissue of a human or animal body to an electromagnetic field, comprising the steps of i) treatment of a skin area of said body with a topical composition comprising one or more reversible mnAChR-antagonists, ii) applying to the treated skin area a measuring device and iii) measuring by means of said measuring device at least one parameter depending on a response to said electromagnetic field; to a method for measuring in vivo the glucose content in blood and to topical compositions useful in said methods
1 - 15 . (canceled)
16 . Method for measuring in vivo the glucose content in blood, comprising the steps of:
i) treating a skin area of a body with a topical composition comprising one or more reversible mnAChR-antagonists,
ii) applying to said skin area a measuring device,
iii) measuring by means of said measuring device at least one parameter depending on a response to an electromagnetic field and
iv) determining the glucose-content.
17 . Method according to claim 16 ,
a. wherein an electromagnetic field is applied by means of one or more field generating electrodes, and
b. wherein said measuring device comprises one or more measuring electrodes.
18 . A method according to claim 16 where said electromagnetic field in is an AC field having a frequency in the range of 1 kHz to 10 GHz.
19 . Method according to claim 16 ,
a. wherein an electromagnetic field is applied by means of a light source emitting UV-, visible or infrared light, and
b. wherein said measuring device comprises one or more light sensitive sensors.
20 . A method according to claim 19 wherein said electromagnetic field is light of a wave-length between 0.2-100 μm.
21 . A method according to claim 20 wherein said light is of a wavelength larger than 0.8 μm.
22 . Method according to claim 16 , wherein said mnAChR-antagonist is selected from the group consisting of natural and synthetic tripeptides.
23 . Method according to claim 22 wherein said tripeptide is a compound of formula (I)
or salt thereof.
24 . A method according to claim 23 , wherein said compound is the diacetate salt.
25 . Method according to claim 16 , wherein said topical composition is a liquid, gel or cream.
26 . Topical composition, comprising
a. 0.1 to 0.001 wt-% of one or more mnAChR-antagonist;
b. 0.01-10 wt-% wt-% hyaluronic acid; and
c. optionally one or more occlusive agents; option-ally one or more humectants; optionally one or more emollients.
27 . Topical composition according to claim 26 , wherein said mnAChR-antagonist, is selected from the group consisting of natural and synthetic tripeptides.
28 . Topical composition according to claim 26 , additionally comprising up to 30 wt-% glycerol and optionally up to 10 wt-% urea.
29 . Topical composition according to claim 26 , in the form of a solution, gel or cream.
30 . A single sachet containing two compartments, wherein one compartment contains a topical composition according to claim 26 , the other compartment contains a cleansing composition.
31 . The method according to claim 16 , wherein the topical composition employed comprises:
a. 0.1 to 0.001 wt-% of one or more mnAChR-antagonist;
b. 0.01-10 wt-% wt-% hyaluronic acid;
c. optionally one or more occlusive agents; optionally one or more humectants; optionally one or more emollients.
32 . The method according to claim 31 , wherein said mnAChR-antagonist from the group consisting of natural and synthetic tripeptides.